IN THE SPOTLIGHT

Lung cancer, target therapy and survival: news for non-small cell form

Lung cancer, target therapy and survival: news for non-small cell form

03/06/2024 - AstraZeneca plc: Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer - Form 6-K

03/06/2024 - AstraZeneca plc: Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer - Form 6-K

TAGRISSO reduces disease progression or death by 84 % in Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

TAGRISSO reduces disease progression or death by 84 % in Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

ASCO: AstraZeneca's Tagrisso, Imfinzi break new grounds in lung cancer—with one standing ovation

ASCO: AstraZeneca's Tagrisso, Imfinzi break new grounds in lung cancer—with one standing ovation

Phase 3 LAURA Trial Primary Results Highlighted in Plenary Session

Phase 3 LAURA Trial Primary Results Highlighted in Plenary Session

Tagrisso Poised to Become Standard of Care in Unresectable Stage III EGFR-Mutated NSCLC

Tagrisso Poised to Become Standard of Care in Unresectable Stage III EGFR-Mutated NSCLC

[ASCO 2024] Osimertinib emerges as an ‘one-fits-all’ treatment for all stages of unresectable EGFRm NSCLC

[ASCO 2024] Osimertinib emerges as an ‘one-fits-all’ treatment for all stages of unresectable EGFRm NSCLC

Improved Outcomes With Subcutaneous Amivantamab in NSCLC

Improved Outcomes With Subcutaneous Amivantamab in NSCLC

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

Improved Outcomes With Subcutaneous vs IV Amivantamab in NSCLC

Improved Outcomes With Subcutaneous vs IV Amivantamab in NSCLC